{"generic":"Daptomycin","drugs":["Cubicin","Daptomycin"],"mono":{"0":{"id":"jvz0s0","title":"Generic Names","mono":"Daptomycin"},"1":{"id":"jvz0s1","title":"Dosing and Indications","sub":[{"id":"jvz0s1b4","title":"Adult Dosing","mono":"<ul><li><b>Bacteremia associated with intravascular line:<\/b> (MRSA) 6 to 8 mg\/kg IV once daily (guideline dosing)<\/li><li><b>Bacteremia associated with intravascular line:<\/b> (methicillin-resistant, coagulase-negative staphylococci; ampicillin-resistant, vancomycin-susceptible Enterococcus faecalis\/faecium; or ampicillin- and vancomycin-resistant Enterococcus faecalis\/faecium) 6 mg\/kg IV once daily (guideline dosing)<\/li><li><b>Bacteremia due to Staphylococcus aureus, Including right-sided endocarditis:<\/b> 6 mg\/kg IV every 24 hours for 2 to 6 weeks (manufacturer dosing)<\/li><li><b>Bacteremia due to Staphylococcus aureus, Including right-sided endocarditis:<\/b> 6 mg\/kg IV every 24 hours for at least 2 weeks in uncomplicated infections or for 4 to 6 weeks in complicated infections; higher doses of 8 to 10 mg\/kg IV every 24 hours recommended by some experts (guideline dosing)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Complicated:<\/b> 4 mg\/kg IV once every 24 hours for 7 to 14 days<\/li><li><b>Osteomyelitis:<\/b> 6 to 8 mg\/kg IV<\/li><li><b>Septic arthritis:<\/b> (MRSA) 6 mg\/kg IV once daily for 3 to 4 weeks (guideline dosing)<\/li><\/ul>"},{"id":"jvz0s1b5","title":"Pediatric Dosing","mono":"Safety and efficacy in pediatric patients not established; avoid use in infants under the age of 12 months "},{"id":"jvz0s1b6","title":"Dose Adjustments","mono":"<ul><li><b>Hepatic impairment, mild to moderate:<\/b> Adjustments not required<\/li><li><b>Renal impairment, complicated skin and skin structure infections, CrCl less than 30 mL\/min:<\/b> 4 mg\/kg IV once every 48 hours for 7 to 14 days<\/li><li><b>Renal impairment, Staphylococcus aureus bloodstream infections, CrCl less than 30 mL\/min:<\/b> 6 mg\/kg IV once every 48 hours for 2 to 6 weeks<\/li><li><b>Hemodialysis, complicated skin and skin structure infections:<\/b> 4 mg\/kg IV once every 48 hours following hemodialysis on hemodialysis days for 7 to 14 days (manufacturer dosing)  OR give dose 3 times a week coinciding with each dialysis session, with an additional 50% of the dose when the interdialytic period will be 72 hours. A dosage increase may also be warranted with intradialytic administration during the final 30 minutes of the session (study dose).<\/li><li><b>Hemodialysis, S aureus bloodstream infections:<\/b> 6 mg\/kg IV once every 48 hours following hemodialysis on hemodialysis days for 2 to 6 weeks (manufacturer dosing)  OR give dose 3 times a week coinciding with each dialysis session, with an additional 50% of the dose when the interdialytic period will be 72 hours. A dosage increase may also be warranted with intradialytic administration during the final 30 minutes of the session (study dose).<\/li><li><b>Continuous ambulatory peritoneal dialysis, complicated skin and skin structure infections:<\/b> 4 mg\/kg IV once every 48 hours for 7 to 14 days<\/li><li><b>Continuous ambulatory peritoneal dialysis, S aureus bloodstream infections:<\/b> 6 mg\/kg IV once every 48 hours for 2 to 6 weeks<\/li><li><b>Continuous venovenous hemodialysis:<\/b> 8 mg\/kg IV every 48 hours resulted in adequate peak levels without accumulation<\/li><\/ul>"},{"id":"jvz0s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bacteremia associated with intravascular line<\/li><li>Bacteremia due to Staphylococcus aureus, Including right-sided endocarditis<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Complicated<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Osteomyelitis<\/li><li>Septic arthritis<\/li><\/ul>"}]},"3":{"id":"jvz0s3","title":"Contraindications\/Warnings","sub":[{"id":"jvz0s3b9","title":"Contraindications","mono":"Hypersensitivity to daptomycin <br\/>"},{"id":"jvz0s3b10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea has been reported; discontinuation may be necessary<\/li><li>Renal:<\/li><li>-- Decreased efficacy in patients with moderate baseline renal impairment<\/li><li>Immunologic:<\/li><li>-- Anaphylaxis and hypersensitivity reactions have been reported; discontinue if suspected<\/li><li>Musculoskeletal:<\/li><li>-- CPK elevations have occurred, especially in patients with renal impairment; monitoring recommended and discontinuation may be necessary<\/li><li>-- Myopathy and rhabdomyolysis have been reported; monitoring recommended and discontinuation may be necessary<\/li><li>Neurologic:<\/li><li>-- Peripheral neuropathy has been reported; monitoring recommended and discontinuation may be necessary<\/li><li>Respiratory:<\/li><li>-- Eosinophilic pneumonia may occur with possibility of reoccurrence with second exposure; discontinue and administer steroids if condition develops<\/li><li>Other:<\/li><li>-- Avoid us in pediatric patients younger than 12 months; risk of potential effects on the muscular, neuromuscular, peripheral nervous, or central nervous systems<\/li><li>-- Staphylococcus aureus infections that are persisting or relapsing may occur<\/li><\/ul>"},{"id":"jvz0s3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jvz0s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jvz0s4","title":"Drug Interactions","sub":{"1":{"id":"jvz0s4b14","title":"Major","mono":"<ul><li>Atorvastatin (theoretical)<\/li><li>Fluvastatin (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Pravastatin (theoretical)<\/li><li>Rosuvastatin (theoretical)<\/li><li>Simvastatin (theoretical)<\/li><\/ul>"}}},"5":{"id":"jvz0s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (5.2% to 11.7%), Vomiting (3.2% to 11.7%)<\/li><li><b>Respiratory:<\/b>Pain in throat (8.3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Renal:<\/b>Renal failure (2.2% to 3.3%)<\/li><li><b>Respiratory:<\/b>Asthmatic pulmonary eosinophilia<\/li><li><b>Other:<\/b>Disease due to Gram-negative bacteria (8.3%)<\/li><\/ul>"},"6":{"id":"jvz0s6","title":"Drug Name Info","sub":{"0":{"id":"jvz0s6b17","title":"US Trade Names","mono":"Cubicin<br\/>"},"2":{"id":"jvz0s6b19","title":"Class","mono":"Antibiotic<br\/>"},"3":{"id":"jvz0s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jvz0s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jvz0s7","title":"Mechanism Of Action","mono":"Daptomycin binds to bacterial cell membranes and causes cell death by inducing rapid depolarization of the membrane potential, leading to disruption of DNA, RNA, and protein synthesis <br\/>"},"8":{"id":"jvz0s8","title":"Pharmacokinetics","sub":{"1":{"id":"jvz0s8b24","title":"Distribution","mono":"<ul><li>Protein binding, primarily albumin: 90% to 93%<\/li><li>Protein binding, renal impairment: 83.5% to 87.6%<\/li><li>Vd: 0.1 L\/kg<\/li><li>Vd, endocarditis and bacteremia: 0.21 L\/kg<\/li><li>Vd, renal impairment: 0.12 to 0.20 L\/kg<\/li><\/ul>"},"3":{"id":"jvz0s8b26","title":"Excretion","mono":"<ul><li>Renal clearance: 0.05 to 0.1 mL\/min\/kg<\/li><li>Renal: 78% unchanged<\/li><li>Fecal: 5.7% unchanged<\/li><li>Dialyzable: Yes (hemodialysis), 15% over 4 hr; Yes (peritoneal), 11% over 4 hr<\/li><li>Total body clearance: 8.3 to 9.1 mL\/hr\/kg<\/li><li>Total body clearance, renal impairment: 5.9 to 9.9 mL\/hr\/kg<\/li><li>Total body clearance, hemodialysis and continuous ambulatory peritoneal dialysis: 3.7 mL\/hr\/kg<\/li><\/ul>"},"4":{"id":"jvz0s8b27","title":"Elimination Half Life","mono":"<ul><li>7.7 to 8.3 hr<\/li><li>Severe renal impairment (CrCl less than 30 mL\/min), 27.83 hr<\/li><li>Hemodialysis and continuous ambulatory peritoneal dialysis, 19.4 to 45.5 hr<\/li><\/ul>"}}},"9":{"id":"jvz0s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Reconstitute 500-mg vial with 10 mL of NS; administer dose either as an IV injection over 2 minutes or further dilute in 50 mL NS and administer as an IV infusion over 30 minutes<\/li><li>Do not mix with additives or other medications or infuse simultaneously through the same IV line<\/li><li>Do not use ReadyMED(R) elastomeric infusion pumps (Cardinal Health, Inc) to store or deliver daptomycin doses; mercaptobenzothiazole (MBT) has been detected in drug samples tested from these pumps<\/li><li>Compatible with NS and LR; incompatible with dextrose-containing solutions<\/li><\/ul>"},"10":{"id":"jvz0s10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><li>liver function tests<\/li><li>repeat blood cultures; in patients with persistent or relapsing Staphylococcus aureus infection or poor clinical response<\/li><li>serum CPK levels, weekly; more frequently in patients with prior or concomitant therapy with an HMG-CoA reductase inhibitor, in patients with renal insufficiency, or in patients who develop unexplained elevations in CPK<\/li><li>signs and symptoms of neuropathy<\/li><li>symptoms of muscle pain\/weakness, especially in distal extremities<\/li><\/ul>"},"11":{"id":"jvz0s11","title":"How Supplied","mono":"<b>Cubicin<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/>"},"13":{"id":"jvz0s13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause constipation, dyspepsia, nausea, vomiting, dizziness, headache, insomnia, dyspnea, or rhabdomyolysis (myalgias, dark urine, arthralgias, fatigue).<\/li><li>Instruct patient to report signs\/symptoms of neuropathy.<\/li><li>Advise patient to report signs\/symptoms of muscle pain\/weakness, especially in distal extremities.<\/li><li>Patient should report diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine.<\/li><li>Instruct patient to avoid using HMG-CoA reductase inhibitors (cholesterol lowering agents such as atorvastatin, fluvastatin, lovastatin, simvastatin) unless approved by healthcare professional, as concurrent use with daptomycin may increase risk of myopathy.<\/li><\/ul>"}}}